GARD® technology.

Genomic Allergen Rapid Detection – GARD® – is an in vitro platform for safety assessment of chemicals. The first GARD® application, GARDskin, is a peer-reviewed assay that is considered for ECVAM validation and prioritized by the Cosmetics Europe Skin Tolerance Task Force.

GARDskin is intended to replace the use of animal experiments in safety assessment of products and product constituents from the cosmetic, chemical and pharmaceutical industry.

In short, cell-cultures with in vivo like features are used as a model for the human immune system, which reacts differentially to allergenic stimulations compared to harmless substances. Following cellular stimulation, the stimulatory agent can be classified according to its hazardous properties by evaluating a set of reporter probes, so-called genomic biomarkers.